Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces its participation in the forthcoming Annual JP Morgan Healthcare Conference in San Francisco, on January 13 to 16, 2014.
By participating at the industry's largest and most informative healthcare investment conference Cardio3 BioSciences will have the opportunity to present an overview of the Company's strategy and key development programs to a broad range of US-based analysts and institutional investors.
Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: "We are pleased to attend the JP Morgan Healthcare Conference. It represents by far the biggest financial healthcare conference of its kind worldwide. This is an excellent opportunity for us to increase the visibility and awareness of our company in the US. Our goal is to position C3BS as the world leader in the field of regenerative medicine for the treatment of heart failure."
SOURCE Cardio3 BioSciences
